
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) – Analysts at HC Wainwright boosted their FY2026 EPS estimates for shares of Enliven Therapeutics in a research report issued on Friday, November 13th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($1.62) per share for the year, up from their prior estimate of ($1.74). HC Wainwright has a “Buy” rating and a $73.00 price target on the stock. The consensus estimate for Enliven Therapeutics’ current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Enliven Therapeutics’ Q4 2026 earnings at ($0.40) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.44) EPS, Q3 2027 earnings at ($0.46) EPS, Q4 2027 earnings at ($0.48) EPS and FY2027 earnings at ($1.80) EPS.
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.09.
Read Our Latest Research Report on Enliven Therapeutics
Enliven Therapeutics Stock Performance
ELVN stock opened at $47.62 on Tuesday. The company’s 50 day moving average is $46.20 and its 200 day moving average is $43.78. Enliven Therapeutics has a 1-year low of $14.78 and a 1-year high of $62.32.
Insider Buying and Selling at Enliven Therapeutics
In other news, Director J. Scott Garland sold 13,000 shares of Enliven Therapeutics stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $46.67, for a total value of $606,710.00. Following the transaction, the director owned 13,000 shares in the company, valued at approximately $606,710. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction dated Monday, October 19th. The shares were sold at an average price of $38.48, for a total value of $231,572.64. Following the completion of the sale, the chief financial officer directly owned 38,000 shares of the company’s stock, valued at approximately $1,462,240. This trade represents a 13.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 25,036 shares of company stock worth $1,141,289. 3.00% of the stock is owned by insiders.
Hedge Funds Weigh In On Enliven Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. KBC Group NV bought a new position in shares of Enliven Therapeutics in the first quarter worth approximately $38,000. Three Bridge Wealth Advisors LLC bought a new stake in Enliven Therapeutics during the 3rd quarter valued at $53,000. Sterling Capital Management LLC raised its holdings in Enliven Therapeutics by 1,180.7% during the 3rd quarter. Sterling Capital Management LLC now owns 1,921 shares of the company’s stock valued at $88,000 after buying an additional 1,771 shares during the last quarter. State of Wyoming bought a new stake in Enliven Therapeutics during the 2nd quarter valued at $96,000. Finally, FNY Investment Advisers LLC purchased a new stake in Enliven Therapeutics during the 2nd quarter valued at $126,000. 95.08% of the stock is currently owned by institutional investors.
About Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. Its research centers on precision oncology, with drug candidates designed to target specific proteins involved in tumor growth. The company’s pipeline has included ELVN-001, an investigational BCR-ABL1 inhibitor being studied for chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor developed for cancers driven by HER2. Enliven is based in Boulder, Colorado.
Featured Articles
- Five stocks we like better than Enliven Therapeutics
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
